Sanne Smith-Apeldoorn

PhD/Epidemiology Student and Psychiatry Resident at University Medical Center Groningen (UMCG) / University of Groningen

Data updated

Papers

6 publications

Trials

0 clinical trials

Links

Research Footprint

Sanne Smith-Apeldoorn appears in 6 tracked papers (2020–2025), most studied alongside Ketamine and Esketamine, across Treatment-Resistant Depression (TRD), Depressive Disorders and Major Depressive Disorder (MDD).

Most-cited paper: Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability (158 citations).

Frequent co-authors: Robert Schoevers, Jeanine Kamphuis and Jolien Veraart.

Background & Research

Sanne Smith-Apeldoorn is a Dutch psychiatrist in training and epidemiology/PhD researcher at the University Medical Center Groningen and University of Groningen. Her research focuses on ketamine and esketamine for difficult-to-treat depression, including efficacy, safety, tolerability, and clinical implementation. She is also involved in broader mood, anxiety, and psychedelic treatment research at UMCG.

Key Impact

She is a clinical researcher publishing systematic reviews and trials on ketamine and esketamine for treatment-resistant depression, with work touching safety in psychosis and medication interactions in psychedelic-adjacent psychiatric treatment.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

3 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Sanne Smith-Apeldoorn is associated with.